Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | PDE5A | O76074 | 7/20 | 0.54 |
| ▸ | GUCY1A1 | Q02108 | 11/20 | 0.53 |
| ▸ | GUCY1B1 | Q02153 | 11/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL15732823 | 0.97 | ADORA3 (0.55) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL257105 | 0.93 | PDE5A (0.58) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL256239 | 0.92 | ADORA3 (0.63) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| Formic Acid SCHEMBL15732878 | 0.90 | PDE5A (0.56) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL10242993 | 0.89 | ADORA3 (0.57) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL256304 | 0.86 | ADORA3 (0.54) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL174871 | 0.81 | ADORA3 (0.61) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL173814 | 0.80 | ADORA3 (0.54) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL255809 | 0.79 | ADORA3 (0.54) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 | |
| SCHEMBL15732792 | 0.79 | ADORA3 (0.55) | ADORA3KCNH2PDE5AGUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611802-B1 | BICYCLIC AZA-HETEROCYCLES AND THEIR USE | BAYER IP GMBH (DE) | 2016-02-24 | — | — | EP | disclosed |
| US-9096592-B2 | Bicyclic aza heterocycles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-04 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-29 | — | — | US | disclosed |
| WO-2012028647-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148433-A1 | BICYCLIC AZA HETEROCYCLES, AND USE THEREOF | AADAC, PAICS, TPMT | ADORA3 814/4885KCNH2 1555/4885PDE5A 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.